United States securities and exchange commission logo





                            October 14, 2022

       Keith Gottesdiener, M.D.
       President and Chief Executive Officer
       Prime Medicine, Inc.
       21 Erie Street
       Cambridge, MA 02139

                                                        Re: Prime Medicine,
Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed October 13,
2022
                                                            File No. 333-267579

       Dear Keith Gottesdiener:

                                                        We have reviewed your
amended registration statement and have the following comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1

       Use of Proceeds, page 86

   1.                                                   Your disclosure that
your development activities are generally not allocated to specific
                                                        programs does not align
with your disclosure that you intend to use $65 million of the
                                                        offering proceeds for
"certain of [y]our current therapeutic programs[.]" Please revise
                                                        and, to the extent that
you plan to use a material portion of the proceeds to fund the
                                                        development of certain
of your current therapeutic programs, please specify these
                                                        programs and separately
quantify the amounts you expect to allocate to each program. If,
                                                        due to the number of
programs you currently have in the discovery stage, or for other
                                                        reasons, you currently
are unable to specify to what stage of development the net proceeds
                                                        from this offering,
together with your existing cash and cash equivalents, and short-term
                                                        investments, will bring
any of your particular programs or product candidates, please
                                                        make that clear.
 Keith Gottesdiener, M.D.
Prime Medicine, Inc.
October 14, 2022
Page 2

       You may contact Tracey Houser at 202-551-3736 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Dillon Hagius at 202-551-7967 or Tim Buchmiller at 202-551-3635 with
any other
questions.



                                                          Sincerely,
FirstName LastNameKeith Gottesdiener, M.D.
                                                          Division of
Corporation Finance
Comapany NamePrime Medicine, Inc.
                                                          Office of Life
Sciences
October 14, 2022 Page 2
cc:       Gabriela Morales-Rivera, Esq.
FirstName LastName